Metabolism in tumor microenvironment: Implications for cancer immunotherapy

被引:152
作者
Shi, Rongchen [1 ]
Tang, Yi-Quan [2 ]
Miao, Hongming [1 ]
机构
[1] Third Mil Med Univ, Army Med Univ, Dept Biochem & Mol Biol, 30 Gaotanyan St, Chongqing 400038, Peoples R China
[2] MRC Lab Mol Biol, Cambridge Biomed Campus, Cambridge, England
来源
MEDCOMM | 2020年 / 1卷 / 01期
基金
中国国家自然科学基金;
关键词
cancer therapy; immunity; metabolism; tumor microenvironment; CD8(+) T-CELLS; METASTATIC UROTHELIAL CARCINOMA; CISPLATIN-INELIGIBLE PATIENTS; L-ARGININE METABOLISM; NF-KAPPA-B; OPEN-LABEL; PD-1; BLOCKADE; MONOCLONAL-ANTIBODIES; GLUCOSE-METABOLISM; DENDRITIC CELLS;
D O I
10.1002/mco2.6
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Tumor microenvironment is a special environment for tumor survival, which is characterized by hypoxia, acidity, nutrient deficiency, and immunosuppression. The environment consists of the vasculature, immune cells, extracellular matrix, and proteins or metabolic molecules. A large number of recent studies have shown that not only tumor cells but also the immune cells in the tumor microenvironment have undergone metabolic reprogramming, which is closely related to tumor drug resistance and malignant progression. Tumor immunotherapy based on T cells gives patients new hope, but faces the dilemma of low response rate. New strategies sensitizing cancer immunotherapy are urgently needed. Metabolic reprogramming can directly affect the biological activity of tumor cells and also regulate the differentiation and activation of immune cells. The authors aim to review the characteristics of tumor microenvironment, the metabolic changes of tumor-associated immune cells, and the regulatory role of metabolic reprogramming in cancer immunotherapy.
引用
收藏
页码:47 / 68
页数:22
相关论文
共 288 条
[1]   CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma [J].
Advani, Ranjana ;
Flinn, Ian ;
Popplewell, Leslie ;
Forero, Andres ;
Bartlett, Nancy L. ;
Ghosh, Nilanjan ;
Kline, Justin ;
Roschewski, Mark ;
LaCasce, Ann ;
Collins, Graham P. ;
Thu Tran ;
Lynn, Judith ;
Chen, James Y. ;
Volkmer, Jens-Peter ;
Agoram, Balaji ;
Huang, Jie ;
Majeti, Ravindra ;
Weissman, Irving L. ;
Takimoto, Chris H. ;
Chao, Mark P. ;
Smith, Sonali M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (18) :1711-1721
[2]   Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma [J].
Afzal, Muhammad Zubair ;
Mercado, Rima R. ;
Shirai, Keisuke .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
[3]   METABOLISM AND ACTION OF AMINO-ACID ANALOG ANTICANCER AGENTS [J].
AHLUWALIA, GS ;
GREM, JL ;
HAO, Z ;
COONEY, DA .
PHARMACOLOGY & THERAPEUTICS, 1990, 46 (02) :243-271
[4]   ARGININE METABOLISM IN WOUNDS [J].
ALBINA, JE ;
MILLS, CD ;
BARBUL, A ;
THIRKILL, CE ;
HENRY, WL ;
MASTROFRANCESCO, B ;
CALDWELL, MD .
AMERICAN JOURNAL OF PHYSIOLOGY, 1988, 254 (04) :E459-E467
[5]   The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance [J].
Allavena, Paola ;
Sica, Antonio ;
Garlanda, Cecilia ;
Mantovani, Alberto .
IMMUNOLOGICAL REVIEWS, 2008, 222 :155-161
[6]   Interleukin-18 up-regulates amino acid transporters and facilitates amino acid-induced mTORC1 activation in natural killer cells [J].
Almutairi, Saeedah Musaed ;
Ali, Alaa Kassim ;
He, William ;
Yang, Doo-Seok ;
Ghorbani, Peyman ;
Wang, Lisheng ;
Fullerton, Morgan D. ;
Lee, Seung-Hwan .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2019, 294 (12) :4644-4655
[7]   From Krebs to clinic: glutamine metabolism to cancer therapy [J].
Altman, Brian J. ;
Stine, Zachary E. ;
Dang, Chi V. .
NATURE REVIEWS CANCER, 2016, 16 (10) :619-634
[8]   PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma [J].
Ansell, Stephen M. ;
Lesokhin, Alexander M. ;
Borrello, Ivan ;
Halwani, Ahmad ;
Scott, Emma C. ;
Gutierrez, Martin ;
Schuster, Stephen J. ;
Millenson, Michael M. ;
Cattry, Deepika ;
Freeman, Gordon J. ;
Rodig, Scott J. ;
Chapuy, Bjoern ;
Ligon, Azra H. ;
Zhu, Lili ;
Grosso, Joseph F. ;
Kim, Su Young ;
Timmerman, John M. ;
Shipp, Margaret A. ;
Armand, Philippe .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (04) :311-319
[9]   Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer [J].
Antonia, S. J. ;
Villegas, A. ;
Daniel, D. ;
Vicente, D. ;
Murakami, S. ;
Hui, R. ;
Yokoi, T. ;
Chiappori, A. ;
Lee, K. H. ;
de Wit, M. ;
Cho, B. C. ;
Bourhaba, M. ;
Quantin, X. ;
Tokito, T. ;
Mekhail, T. ;
Planchard, D. ;
Kim, Y. -C. ;
Karapetis, C. S. ;
Hiret, S. ;
Ostoros, G. ;
Kubota, K. ;
Gray, J. E. ;
Paz-Ares, L. ;
de Castro Carpeno, J. ;
Wadsworth, C. ;
Melillo, G. ;
Jiang, H. ;
Huang, Y. ;
Dennis, P. A. ;
Ozguroglu, M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20) :1919-1929
[10]   mTOR regulates memory CD8 T-cell differentiation [J].
Araki, Koichi ;
Turner, Alexandra P. ;
Shaffer, Virginia Oliva ;
Gangappa, Shivaprakash ;
Keller, Susanne A. ;
Bachmann, Martin F. ;
Larsen, Christian P. ;
Ahmed, Rafi .
NATURE, 2009, 460 (7251) :108-U124